Prot #CT7001_003 (SUMIT-ELA): A Phase 1b/2 Open-Label Study of Samuraciclib in Combination with Elacestrant in Participants with Metastatic or Locally Advanced Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Project: Research project

Project Details

StatusActive
Effective start/end date5/2/245/2/27

Funding

  • Fortrea, Inc. (Prot #CT7001_003 (SUMIT-ELA) // Prot #CT7001_003 (SUMIT-ELA))
  • Carrick Therapeutics Ltd (Prot #CT7001_003 (SUMIT-ELA) // Prot #CT7001_003 (SUMIT-ELA))